Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | C5 | P01031 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carprofen SCHEMBL29930903 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL30910956 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL30910972 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL3909 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL29743273 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL3698103 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL5055325 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL3910 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL30910975 | 1.00 | PTGS2 (1.00) | PTGS2MEN1ABCC4C5MAPT | |
| Carprofen SCHEMBL9814869 | 0.99 | PTGS2 (0.97) | PTGS2MEN1ABCC4C5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094681-A | Carbazole compounds and therapeutic use thereof in the treatment of respiratory infections | — | 2026-05-26 | — | — | CN | disclosed |
| EP-4743082-A1 | CARBAZOLE COMPOUNDS AND THEIR USE IN THERAPY, IN THE TREATMENT OF A RESPIRATORY INFECTION | UCL Business Ltd (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-12589074-B2 | Tablets having discontinuous coated regions | KENVUE BRANDS LLC (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4687841-A1 | THERAPEUTIC SUSPENSION COMPOSITIONS | Kenvue Brands LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4691492-A2 | LIQUID COMPOSITIONS | Kenvue Brands LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4687840-A1 | THERAPEUTIC LIQUID COMPOSITIONS | Kenvue Brands LLC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034142-A1 | Therapeutic Compounds and Compositions for Treating Social Disorders and Substance Use Disorders | Kinoxis Therapeutics Pty Ltd (AU) | 2026-02-05 | — | — | US | disclosed |
| EP-4678237-A2 | 5-HT7 ANTAGONIST FOR THE TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES | Medizinische Hochschule Hannover (MHH) (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-12458648-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | KINOXIS THERAPEUTICS PTY LTD. (AU) | 2025-11-04 | — | — | US | disclosed |
| EP-3856156-B1 | 5-HT7 ANTAGONIST FOR THE TREATMENT OF DEMENTIA-ASSOCIATED TAUOPATHIES | MEDIZINISCHE HOCHSCHULE HANNOVER MHH (DE) | 2025-10-29 | — | — | EP | disclosed |
| EP-3328864-B1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS FOR TREATING SOCIAL DISORDERS AND SUBSTANCE USE DISORDERS | Kinoxis Therapeutics Pty Ltd (AU) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022159506-A1 | DEUTERATED CANNABIDIOL COMPOUNDS | MERIT THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| CN-114787607-A | Improved light transmissive sample holder and multi-wavelength analysis | ESSENLIX 公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-3386520-B1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | UNIV CALIFORNIA (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-4017523-A1 | UBE3A FOR THE TREATMENT OF ANGELMAN SYNDROME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022129476-A1 | A COMPOSITION FOR USE IN THE TREATMENT OF INTERVERTEBRAL DISC HERNIATION | STAYBLE THERAPEUTICS AB (SE) | 2022-06-23 | — | — | WO | disclosed |
| US-11318166-B2 | Method for non surgical repair of vertebral compression fractures | CEDARS-SINAI MEDICAL CENTER (US) | 2022-05-03 | — | — | US | disclosed |
| US-11298324-B2 | Rapidly disintegrating gelatinous coated tablets | JOHNSON & JOHNSON CONSUMER INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220062173-A1 | LIQUID COMPOSITIONS | JOHNSON & JOHNSON CONSUMER INC. | 2022-03-03 | — | — | US | disclosed |
| EP-2099823-B2 | VARIANT TARGET BINDING AGENTS AND USES THEREOF | SEAGEN INC (US) | 2022-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458648-B2 | Therapeutic compounds and compositions for treating social disorders and substance use disorders | SLC18A2, SLC6A3, CES2 | PTGS2 1625/4885MEN1 4046/4885ABCC4 778/4885 |
| US-20220062173-A1 | LIQUID COMPOSITIONS | TSLP, CFTR, CCL11 | PTGS2 252/4885MEN1 4339/4885ABCC4 474/4885 |
| US-12589074-B2 | Tablets having discontinuous coated regions | TAS2R41, TAS2R1, TAS2R9 | PTGS2 3868/4885MEN1 961/4885ABCC4 955/4885 |
| US-20260034142-A1 | Therapeutic Compounds and Compositions for Treating Social Disorders and Substance Use Disorders | SLC6A3, SLC6A4, SLC6A1 | PTGS2 4609/4885MEN1 4434/4885ABCC4 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.